Pharmadrug Inc
Pharmadrug Inc. operates as a specialty pharmaceutical company. The company focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. It also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs fo… Read more
Pharmadrug Inc (LMLLF) - Net Assets
Latest net assets as of September 2025: $-1.51 Million USD
Based on the latest financial reports, Pharmadrug Inc (LMLLF) has net assets worth $-1.51 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($557.24K) and total liabilities ($2.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.51 Million |
| % of Total Assets | -270.95% |
| Annual Growth Rate | N/A |
| 5-Year Change | -111.77% |
| 10-Year Change | -115.96% |
| Growth Volatility | 430.6 |
Pharmadrug Inc - Net Assets Trend (2012–2024)
This chart illustrates how Pharmadrug Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharmadrug Inc (2012–2024)
The table below shows the annual net assets of Pharmadrug Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.24 Million | +15.11% |
| 2023-12-31 | $-1.47 Million | -116.59% |
| 2022-12-31 | $8.84 Million | -47.61% |
| 2021-12-31 | $16.87 Million | +59.54% |
| 2020-12-31 | $10.57 Million | +137.12% |
| 2019-12-31 | $4.46 Million | +1009.22% |
| 2018-12-31 | $-490.32K | -720.95% |
| 2017-12-31 | $78.96K | +85.59% |
| 2016-12-31 | $42.55K | -99.45% |
| 2015-12-31 | $7.79 Million | -1.72% |
| 2014-12-31 | $7.93 Million | +1136.69% |
| 2013-12-31 | $641.25K | -44.22% |
| 2012-12-31 | $1.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmadrug Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3910717700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $33.99 Million | % |
| Other Comprehensive Income | $-31.38K | % |
| Other Components | $3.75 Million | % |
| Total Equity | $-1.40 Million | 100.00% |
Pharmadrug Inc Competitors by Market Cap
The table below lists competitors of Pharmadrug Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Entheon Biomedical Corp
OTCQB:ENTBF
|
$997.84K |
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
$998.05K |
|
SRIVARU Holding Limited
PINK:SVUHF
|
$998.48K |
|
OSHKOSH
BE:OK3
|
$998.62K |
|
Tie Holding NV
F:TJH7
|
$995.84K |
|
ALPHA MOS INH.EO 020
F:0MV
|
$995.82K |
|
d'Alba Global
KO:483650
|
$995.62K |
|
Brigadier Gold Limited
PINK:BGADF
|
$994.82K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmadrug Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,704,675 to -1,403,341, a change of 301,334.
- Net loss of 793,000 reduced equity.
- New share issuances of 326,000 increased equity.
- Other comprehensive income increased equity by 14,227.
- Other factors increased equity by 754,107.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-793.00K | -56.51% |
| Share Issuances | $326.00K | +23.23% |
| Other Comprehensive Income | $14.23K | +1.01% |
| Other Changes | $754.11K | +53.74% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Pharmadrug Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $14.58 | $0.01 | x |
| 2012-12-31 | $15.16 | $0.01 | x |
| 2013-12-31 | $6.85 | $0.01 | x |
| 2014-12-31 | $16.86 | $0.01 | x |
| 2015-12-31 | $12.01 | $0.01 | x |
| 2016-12-31 | $0.07 | $0.01 | x |
| 2017-12-31 | $0.15 | $0.01 | x |
| 2018-12-31 | $-0.25 | $0.01 | x |
| 2019-12-31 | $0.30 | $0.01 | x |
| 2020-12-31 | $0.46 | $0.01 | x |
| 2021-12-31 | $0.36 | $0.01 | x |
| 2022-12-31 | $0.18 | $0.01 | x |
| 2023-12-31 | $-0.03 | $0.01 | x |
| 2024-12-31 | $-0.01 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmadrug Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1408.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -17.18% | 0.00% | 0.00x | 1.02x | $-312.48K |
| 2013 | -63.63% | 0.00% | 0.00x | 1.19x | $-472.13K |
| 2014 | -21.94% | 0.00% | 0.00x | 1.04x | $-2.53 Million |
| 2015 | -5.08% | 0.00% | 0.00x | 1.01x | $-1.18 Million |
| 2016 | -17657.70% | 0.00% | 0.00x | 2.69x | $-7.52 Million |
| 2017 | -145.43% | 0.00% | 0.00x | 1.27x | $-122.74K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.84 Million |
| 2019 | -211.22% | -1030.17% | 0.06x | 3.49x | $-6.59 Million |
| 2020 | -55.18% | -753.29% | 0.05x | 1.47x | $-6.08 Million |
| 2021 | -34.83% | -83806.53% | 0.00x | 1.16x | $-7.56 Million |
| 2022 | -100.46% | 0.00% | 0.00x | 1.37x | $-9.76 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.03 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-652.67K |
Industry Comparison
This section compares Pharmadrug Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmadrug Inc (LMLLF) | $-1.51 Million | -17.18% | N/A | $996.23K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |